Goldman Sachs Reiterates Buy on Medtronic (MDT)

Goldman Sachs is out with its report today on Medtronic MDT, reiterating Buy.

In a note to clients, Goldman Sachs writes, "We reiterate our Buy rating on shares of Medtronic and do not view the AMPLIFY delay as significant to our thesis. It is also worth noting that InFuse has essentially been on “auto-pilot” for some time. Sales are not part of rep compensation packages, and the product is essentially selling itself (evidenced by its strong ranking in our survey - despite lack of aggressive promotion)."

At the time of posting, shares of MDT were trading pre-market at $37.35, down 1.92% from Friday's close.